Legend Biotech Corporation (LEGN)

Legend Biotech Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Jan 1, 2020
Cash & Equivalents	201.25	1,278	786.03	688.94	455.69	83.36
Short-Term Investments	1,048	30.34	54.02	193.46	50	75.56
Trading Asset Securities	42.2	0.66	185.6	-	-	-
Cash & Short-Term Investments	1,292	1,309	1,026	882.4	505.69	158.92
Cash Growth	-14.72%	27.60%	16.23%	74.49%	218.20%	-26.49%
Accounts Receivable	13.41	101.43	0.28	50.5	75.62	30
Other Receivables	87.97	55.63	44.24	8.04	7	-
Receivables	101.38	157.06	44.52	58.55	82.62	30
Inventory	18.87	19.43	10.35	1.75	1.8	1.16
Prepaid Expenses	12.32	12.23	17.33	5.72	3.46	21.67
Other Current Assets	0.43	0.36	1.27	1.44	0.38	0.26
Total Current Assets	1,425	1,498	1,099	949.85	593.94	212.01
Property, Plant & Equipment	219.74	189.23	160.76	140.79	111.88	72.98
Long-Term Investments	4.4	4.36	-	4.71	-	-
Other Intangible Assets	2.77	4.06	3.41	4.68	2.85	0.52
Long-Term Accounts Receivable	-	0.29	0.4	-	-	-
Other Long-Term Assets	146.44	152.88	67.28	19.44	13.41	7.11
Total Assets	1,798	1,849	1,331	1,119	722.09	292.62
Accounts Payable	39.49	20.16	32.89	7.04	4.91	9.59
Accrued Expenses	132.5	105.41	152.73	104.38	74.36	-
Short-Term Debt	-	-	-	-	0.33	-
Current Portion of Leases	3.33	3.18	3.56	0.91	1.46	1.03
Current Income Taxes Payable	6.57	7.2	9.77	9.49	8.8	12.78
Current Unearned Revenue	75.39	53.08	0.45	0.3	0.28	-
Other Current Liabilities	37.03	27.39	98.38	107.08	25.42	70.85
Total Current Liabilities	294.3	216.42	297.79	229.2	115.57	94.25
Long-Term Debt	291.56	281.33	260.93	120.46	-	-
Long-Term Leases	44.04	44.17	20.04	1.59	1.91	5.06
Long-Term Unearned Revenue	9.28	55.27	7.66	1.87	2.05	-
Long-Term Deferred Tax Liabilities	-	-	-	-	4.24	41.99
Other Long-Term Liabilities	-	0.06	0.23	0.4	0.55	-
Total Liabilities	639.18	597.24	586.65	353.52	124.32	141.3
Common Stock	0.04	0.04	0.03	0.03	0.03	0.02
Additional Paid-In Capital	2,675	2,637	1,657	1,261	708.31	3.91
Retained Earnings	-1,563	-1,485	-966.46	-520.11	-116.53	149.85
Comprensive Income & Other	46.45	98.93	53.72	24.57	5.96	-2.45
Shareholders' Equity	1,159	1,251	744.31	765.94	597.77	151.32
Total Liabilities & Equity	1,798	1,849	1,331	1,119	722.09	292.62
Total Debt	338.93	328.67	284.53	122.97	3.7	6.09
Net Cash (Debt)	952.91	980.05	741.12	759.43	501.99	152.84
Net Cash Growth	-20.34%	32.24%	-2.41%	51.28%	228.45%	-27.77%
Net Cash Per Share	5.23	5.57	4.66	5.39	4.25	1.53
Filing Date Shares Outstanding	183.17	181.91	165.07	154.23	133.01	100
Total Common Shares Outstanding	183.17	181.91	165.07	154.23	133.01	100
Working Capital	1,131	1,281	801.33	720.65	478.38	117.76
Book Value Per Share	6.33	6.88	4.51	4.97	4.49	1.51
Tangible Book Value	1,156	1,247	740.9	761.26	594.92	150.8
Tangible Book Value Per Share	6.31	6.86	4.49	4.94	4.47	1.51
Land	-	2.89	2.89	2.89	2.89	2.89
Buildings	-	65.54	45.08	16.01	11.21	10.07
Machinery	-	49.14	46.26	38.27	29.17	22.14
Construction In Progress	-	3.04	14.18	41.37	27.81	3.69
Leasehold Improvements	-	23.12	21.97	20.91	11.89	10.38

Source: S&P Capital IQ. Standard template. Financial Sources.